Bemarituzumab
- Generic Name
- Bemarituzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1952272-74-0
- Unique Ingredient Identifier
- RJW23BQ0KW
- Background
Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 303
- Registration Number
- NCT05325866
- Locations
- ๐ญ๐บ
Orszagos Onkologiai Intezet, Budapest, Hungary
๐บ๐ธUS Oncology Regulatory Affairs Corporate Office, Irving, Texas, United States
๐บ๐ธUS Oncology Research Investigational Products Center, Irving, Texas, United States
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT05322577
- Locations
- ๐ฏ๐ต
Ishikawa Prefectural Central Hospital, Kanazawa-shi, Ishikawa, Japan
๐ฏ๐ตKagawa University Hospital, Kita-gun, Kagawa, Japan
๐บ๐ธNorthport Veterans Affairs Medical Center, Northport, New York, United States
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT05267470
- Locations
- ๐จ๐ณ
Taipei Veterans General Hospital, Taipei, Taiwan
๐จ๐ณLinkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Taiwan
๐บ๐ธMontefiore Einstein Center for Cancer Care, Bronx, New York, United States
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 507
- Registration Number
- NCT05111626
- Locations
- ๐บ๐ธ
Greater Baltimore Medical Center, Baltimore, Maryland, United States
๐บ๐ธUniversity of Illinois Chicago, Chicago, Illinois, United States
๐บ๐ธProvidence Portland Medical Center, Portland, Oregon, United States
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 547
- Registration Number
- NCT05052801
- Locations
- ๐ฌ๐ท
251 General Airforce Hospital, Athens, Greece
๐ฌ๐ทGeneral Hospital of Athens Laiko, Athens, Greece
๐ฌ๐ทEvgenidio Hospital I Agia Trias, Athens, Greece
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 80
- Registration Number
- NCT02213289
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.